...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition
【24h】

Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition

机译:蛋白酪氨酸磷酸酶受体S通过控制超热生长因子受体诱导的上皮-间质转化,在肝细胞癌中起转移抑制作用

获取原文
获取原文并翻译 | 示例

摘要

Hepatocellular carcinoma (HCC) is the third-most lethal cancer worldwide. Understanding the molecular pathogenesis of HCC recurrence and metastasis is the key to improve patients' prognosis. In this study, we report that protein tyrosine phosphatase receptor S (PTPRS) is significantly down-regulated in nearly 80% of HCCs, and its expression negatively correlates with aggressive pathological features, such as larger tumor size and advanced stage. In addition, PTPRS deficiency is independently associated with shorter survival and increased recurrence in patients, although 16.7% of HCCs show intratumor heterogeneous expression of PTPRS. Restoration of wild-type, but not mutant, PTPRS expression significantly inhibits HCC cell migration and invasion in vitro as well as lung metastasis in vivo, whereas knockdown of its expression significantly promotes invasion and metastasis. Notably, PTPRS-regulated HCC invasiveness is accompanied by typical changes of epithelial-mesenchymal transition (EMT). Moreover, PTPRS forms a complex with epithermal growth factor receptor (EGFR) and regulates its tyrosine residues' phosphorylation. Ectopic expression of EGFR reverses the metastasis-inhibiting effects of PTPRS, whereas silencing of EGFR or inhibiting phosphorylation of key molecules in EGFR downstream pathways reinhibits EMT and metastasis caused by PTPRS down-regulation. Meanwhile, promoter hypermethylation of PTPRS is frequently detected in HCC samples and cell lines. Treatment with a demethylation agent, 5-aza-2-deoxycytidine, recovers PTPRS expression in a dose-dependent manner. Conclusions: Epigenetic inactivation of PTPRS may increase phosphorylation and activity of EGFR signaling to promote EMT and metastasis in HCC. (Hepatology 2015;62:1201-1214)
机译:肝细胞癌(HCC)是全球第三大致死性癌症。了解肝癌复发和转移的分子机制是改善患者预后的关键。在这项研究中,我们报告蛋白质酪氨酸磷酸酶受体S(PTPRS)在近80%的HCC中显着下调,并且其表达与侵袭性病理特征(例如更大的肿瘤大小和晚期)负相关。此外,尽管16.7%的HCC显示PTPRS的肿瘤内异质表达,但PTPRS缺乏与患者较短的生存时间和更高的复发率独立相关。恢复野生型而非突变体的PTPRS表达可显着抑制HCC细胞在体外的迁移和侵袭以及体内的肺转移,而降低其表达可显着促进侵袭和转移。值得注意的是,PTPRS调节的HCC侵袭性伴随着上皮-间质转化(EMT)的典型变化。此外,PTPRS与超热生长因子受体(EGFR)形成复合物,并调节其酪氨酸残基的磷酸化。 EGFR的异位表达逆转了PTPRS的转移抑制作用,而EGFR沉默或抑制EGFR下游通路中关键分子的磷酸化则重新抑制了PTPRS下调引起的EMT和转移。同时,在HCC样品和细胞系中经常检测到PTPRS的启动子高甲基化。用脱甲基剂5-氮杂-2-脱氧胞苷处理以剂量依赖性方式恢复PTPRS表达。结论:PTPRS的表观遗传失活可能增加EGFR信号转导的磷酸化和活性,从而促进肝癌的EMT和转移。 (肝病2015; 62:1201-1214)

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号